FDA

Active regulatory review of multiple psychedelic INDs

The FDA is the US federal agency responsible for approving new drugs. Rejected Lykos Therapeutics' MDMA-assisted therapy NDA in August 2024 via Complete Response Letter. Has cleared INDs for multiple psychedelic research programs including Compass Pathways' COMP360 for PTSD.

Coverage

Week in Review: The EPIsoDE Trial, a $1.2B Acquisition, and the State of State Policy 2026-04-03 Compass Pathways Moves Into PTSD, and Americans Are Coming Around on Psilocybin 2026-04-02 State-Level Psychedelic Policy Is Getting Complicated 2026-04-01 News Digest: VA Office, Microdosing Reality Check, 5-MeO-DMT Clinical Hold Lifted 2026-03-31 Otsuka Pays $1.2 Billion for Methylone Developer Transcend 2026-03-31

Related

Compass PathwaysCybinLykos TherapeuticsIbogaineMDMAPsilocybinMDMA-Assisted TherapyTreatment-Resistant Depression (TRD)

External

FDA.gov